COMP <GO>
LMAT vs INSP // EV/EBITDA & P/E VALUATION
LeMaitre Vascular Inc. (NASDAQ) VS. Inspire Medical Systems Inc. (NYSE) • 15-METRIC TALLY: LMAT 7
— INSP 6
▲ EV/EBITDA & P/E VALUATION LEADER: INSP
LAST: $85.27 (+2.90%) • MKT CAP: $1.95B
valuation
28.3x
LAST: $71.18 (+0.30%) • MKT CAP: $2.06B
valuation
23.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMAT VS. INSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMAT | INSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.50% | 85.40% | -13.90 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | 6.00% | +8.70 | LMAT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 28.3x | 23.3x | +5.00 | INSP | /valuation <GO> |
| Free Cash Flow Yield | 4.17% | 3.81% | +0.36 | LMAT | /fcf-yield <GO> |
| Operating Margin | 27.20% | 5.60% | +21.60 | LMAT | /operating-margins <GO> |
| Net Profit Margin | 23.10% | 15.90% | +7.20 | LMAT | /net-margins <GO> |
| Revenue Growth (YoY) | 13.50% | 13.60% | -0.10 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.93% | 0.00% | +0.93 | LMAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.30 | 11.40 | -4.10 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.4 | 45.4 | +0.02 | LMAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.4x | 11.9x | +16.50 | INSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $2.06B | -$107.8M | INSP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMAT REV | INSP REV | LMAT GROSS % | INSP GROSS % | LMAT FCF | INSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $249.6M | $912.0M | 71.5% | 85.4% | $81.3M | $78.5M |
| FY 2024 | $219.9M | $802.8M | 68.6% | 84.7% | $44.1M | $91.1M |
| FY 2023 | $193.5M | $624.8M | — | — | $36.8M | $24.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMAT // BETA —
INSP // BETA —